SEQUENCE LISTING

- <110> Cohen, David I.
- <120> Tat-based Immunomodulatory Compositions and Methods for Their Discovery and Use
- <130> 51311-00009
- <140> US 10/598,978
- <141> 2006-09-15
- <150> 60/553,733
- <151> 2004-03-16
- <150> PCT/US05/008694
- <151> 2005-03-16
- <160> 11
- <170> PatentIn version 3.3
- <210> 1
- <211> 101
- <212> PRT
- <213> Human immunodeficiency virus type 1
- <400> 1
- Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$
- Gln Pro Lys Thr Ala Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe $20 \\ 25 \\ 30$
- His Cys Gln Val Cys Phe Thr Lys Lys Ala Leu Gly Ile Ser Tyr Gly 35 40 45
- Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Glu Asp Ser Gln Thr 50 55 60
- His Gln Val Ser Pro Pro Lys Gln Pro Ala Pro Gln Phe Arg Gly Asp 65 70 75 80
- Pro Thr Gly Pro Lys Glu Ser Lys Lys Lys Val Glu Arg Glu Thr Glu 85 90 95

Thr His Pro Val Asp 100

```
<210>
       2
<211>
       303
<212>
       DNA
       Human immunodeficiency virus type 1
<213>
<400>
                                                                       60
atggageeeg tggaeeeteg eetggageee tggaageaee egggeageea geeeaagaee
qeetgeacca catgttactg caagaagtge tgettecact gecaggtgtg etteaccaag
                                                                      120
aaggeettgg geateageta eggeegeaag aagegeegge agegeegeeg ggeeeetgag
                                                                      180
qacaqccaga cccaccaggt gagccctccc aagcagcccg ctccacagtt ccgcggcgac
                                                                      240
                                                                      300
cctaccggtc ccaaggagag caagaagaag gtggagcgcg agaccgagac ccatcccgtc
                                                                      303
qac
<210>
       3
<211>
       17
<212>
       PRT
<213> Human immunodeficiency virus type 1
<400> 3
Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
                                     10
Lys
<210>
<211>
       21
       PRT
<212>
<213>
       Human immunodeficiency virus type 1
<400>
      4
Pro Cys Asp Trp Pro Leu Thr Pro Asp Pro Trp Val Tyr Ser Gly Ser
                5
                                     10
                                                         15
Gln Pro Lys Val Pro
            20
<210>
       5
<211>
       27
<212>
<213>
       Simian immunodeficiency virus
<400>
```

Pro Leu Arg Glu Glu Asn Ser Leu Glu Ser Ser Asn Glu Arg Ser

Ser Cys Ile Leu Glu Ala Asp Ala Thr Thr Pro

20

<210> <211> 11 <212> PRT <213> Human immunodeficiency virus type 1 <400> 6 Ser Asn Glu Arg Ser Ser Cys Glu Leu Glu Val 5 <210> 7 <211> 16 <212> Human immunodeficiency virus type 1 <213> <400> 7 Cys Thr Thr Cys Tyr Cys Lys Cys Cys Phe His Cys Gln Val Cys 5 10 <210> 8 <211> 50 <212> DNA <213> Human immunodeficiency virus type 1 <400> 8 ccagtagatc ctagactaga gccctggaag catccaggaa gtcagcctaa 50 <210> 9 <211> 63 <212> DNA <213> Mus musculus <400> 9 ccatgtgact ggcccctgac cccgcacccc tgggtatact ccgggggcca gcccaaagtg 60 ccc 63 <210> 10 33 <211> <212> <213> Simian immunodeficiency virus <400> 10 agcaacgagc ggagttcctg cgagttagag gtg 33 <210> 11

<211> 98

<212> PRT

<213> Artificial

<220>

<223> Modified immunostimulatory Tat

<400> 11

Met Glu Pro Ser Asn Glu Arg Ser Ser Cys Glu Leu Glu Val Pro Lys $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$

Thr Ala Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe His Cys Gln 20 25 30

Val Cys Phe Thr Lys Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys 35 40 45

Arg Arg Gln Arg Arg Ala Pro Glu Asp Ser Gln Thr His Gln Val
50 55 60

Ser Pro Pro Lys Gln Pro Ala Pro Gln Phe Arg Gly Asp Pro Thr Gly 65 70 75 80

Pro Lys Glu Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Thr His Pro 85 90 95

Val Asp